Ctxt Pty Limited

Cancer Therapeutics Crc Pty Limited

Benjamin Joseph Morrow

Michelle Ang Camerino

Paul Anthony Stupple

Richard Charles Foitzik

Scott Raymond Walker

Romina Lessene

Danny Ganame

Andrew John Harvey

Ian Peter Holmes

Ylva Elisabet Bergman

Gillian Elizabeth Lunniss

Catherine Fae Hemley

H Rachel Lagiakos

Wilhelmus Johannes Antonius Kersten

John Feutrill

Jonathan Grant Hubert

Graeme Irvine Stevenson

Anthony Nicholas Cuzzupe

Ylva Elisabet Bergman Bozikis

Neil Choi

Helen Rachel Lagiakos

Matthew Lloyd Dennis

This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prevention of diseases ameliorated by the modulation of STING.

Compound modulators of sting

A compound of formula (I): wherein: Y is (CH2)n, where n is from 2 to 4; W1 and W11 are independently selected from OH and ORP, where RP is Me or Et.

Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting

A compound of formula (I), wherein Ris selected from (i) H, (ii) Ccycloalkyl, (iii) Cheterocyclyl optionally substituted with a group selected from: methyl and ester, and (iv) linear or branched Calkyl optionally substituted with a group selected from: alkoxy, amino, amido, acylamido, acyloxy, alkyl carboxyl ester, alkyl carbamoyl, alkyl carbamoyl ester, phenyl, phosphonate ester, Cheterocyclyl optionally substituted with a group selected from methyl and oxo, and a naturally occurring amino acid, optionally N-substituted with a group selected from methyl, acetyl and boc; Ais CRor N; Ais CRor N; Ais CRor N; Ais CRor N; where no more than two of A, A, A, and Amay be N; one or two of R, R, R, and R, (if present) are selected from H, F, Cl, Br, Me, CF, cyclopropyl, cyano, OMe, OEt, CHOH, CHOMe and CHNMe; the remainder of R, R, R, and R, (if present) are H; Y is O, NH or CH; Ris selected from: (RYA) and (RYB).

Substituted condensed thiophenes as modulators of sting

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris either H or Me; Ris either H or Me; Rand Rare independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Tetrahydroisoquinoline derived PRMT5-inhibitors

A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; Ris H or Me; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand R(if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris selected from OH, &#x2014;NH, &#x2014;C(&#x2550;O)NH, and &#x2014;CHOH; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

VEGFR3 inhibitors

This invention relates to a compound of the formula (I):  The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

Growing community of inventors

Parkville, Australia

Benjamin Joseph Morrow